Bionpharma Inc

Founded in 1994, Ranbaxy Pharmaceuticals offers various research and development services, such as laboratory tests, clinical research, drug development, in-licensing, promotion, distribution and marketing support solutions. The company provides a range of tablets, caplets, capsules, laxatives, antacids and analgesics for cough and cold, diabetes and skin treatments. It offers products under the brand names of Proctosol, Riomet, Sotret, Flomax and Cipro. Ranbaxy Pharmaceuticals also provides various formulations for the commercial production of ibuprofens, acetaminophens, pseudoephedrines and ciprofloxacin products. The company distributes its products in more than 125 countries worldwide. It is a wholly owned subsidiary of Ranbaxy Laboratories Limited, which manufactures a variety of generic and patented pharmaceuticals.

Belrose Pharma Inc, located in Cranbury, NJ, specializes in cancer treatment by harnessing the power of the p53 protein, which is crucial in responding to DNA damage. With over 40 years of experience in p53 research, the company focuses on restoring mutated p53 to regain its tumor-suppressing function through innovative structural correction techniques. The company is committed to advancing its drug discovery pipeline and actively participates in clinical trials to bring new therapies to market. Belrose Pharma fosters a dynamic work environment that encourages bold thinking and seamless execution among its diverse team, all aimed at conquering cancer. Generated from the website

CorMedix Inc is a pharmaceutical company based in Bedminster, NJ, specializing in the research, development, and commercialization of therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Their flagship product, DefenCath, has been approved by the U.S. FDA to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in patients receiving hemodialysis. With a dedicated management team, board of directors, and scientific advisory board, CorMedix is committed to advancing their pipeline of products, including LOCK-IT-100 and taurolidine, through early science research and development. The company also actively engages with investors, media, and the scientific community through publications, presentations, and events, ensuring transparency and corporate governance.Generated from the website